Covidien Prevails in Patent Action against Applied Medical Resources
Covidien (NYSE: COV) announced that it has prevailed against Applied Medical Resources Corp. in a patent action before the U.S. District Court, Central District of California.
In granting Covidien's motion of summary judgment, the District Court ruled that Covidien's trocar products do not infringe Applied Medical's patent. In May 2011, Applied Medical sued Covidien in connection with Covidien's sale of certain trocar products.
“We are pleased that the Court recognized that Covidien's trocar products are differentiated from our competitors,” said Scott Herring, Vice President, Endomechanical and Energy Division, Covidien Surgical Solutions
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.